What is the appropriate further management for a 2 cm carcinoma of the penile glans?

Management of 2 cm Penile Glans Carcinoma

For a 2 cm invasive carcinoma confined to the glans penis, perform organ-sparing glansectomy (partial or complete) with surgical margins ≥1 mm, followed by immediate inguinal lymph node staging based on pathologic risk stratification. 1

Primary Tumor Management

Surgical Approach

• Glansectomy is the preferred organ-sparing technique for cT1/T2 tumors confined to the glans, providing excellent oncologic control while preserving penile length and function. 1, 2

• Achieve surgical margins of at least 1 mm from the tumor—the 2018 data from supraregional referral centers demonstrate that local recurrence rates only increase significantly when margins are <1 mm, eliminating the need for traditional 2 cm margins. 1

• Obtain intraoperative frozen section analysis of margins to ensure complete excision during the initial procedure, as resection (versus ablation) provides complete histopathological staging and detects occult invasion present in up to 20% of cases. 1

• Glansectomy achieves 5-year recurrence-free survival of 76-82% in appropriately selected patients, with local recurrence rates of only 7.6% and excellent cancer-specific survival of 99% at 5 years. 1, 2, 3

Pre-operative Assessment

• Perform MRI of the penis when uncertainty exists regarding corporal invasion or surgical feasibility—this imaging determines whether organ-sparing surgery is technically possible versus requiring partial penectomy. 1

• Obtain a biopsy before surgery only if malignancy is not clinically obvious or if non-surgical treatment is planned; otherwise, proceed directly to excision for definitive histopathology. 1

• Document tumor size, location, morphology, and proximity to the urethral meatus during physical examination to plan the surgical approach. 1

Inguinal Lymph Node Management

Risk Stratification and Staging

• All patients with pathologic T1b or higher disease require surgical lymph node staging due to high rates of micrometastatic disease that are not clinically detectable. 1, 4

• Perform inguinal ultrasound with fine-needle aspiration of any sonographically abnormal nodes before proceeding to dynamic sentinel node biopsy (DSNB), as this may upstage patients and alter the surgical plan. 1

• Dynamic sentinel node biopsy is the preferred staging method for clinically node-negative (cN0) patients, offering accurate staging with lower morbidity than complete inguinal lymph node dissection. 1

• If DSNB is unavailable and referral is not feasible, perform inguinal lymph node dissection (open or video-endoscopic) as the alternative staging approach. 1

Management of Palpable Nodes

• Obtain image-guided biopsy confirmation of any palpable or suspicious inguinal nodes before treatment, as clinical examination alone is unreliable. 1

• For confirmed cN+ disease, perform 18F-FDG PET-CT or CT chest/abdomen to exclude distant metastases before initiating treatment, as this determines whether curative surgery is appropriate. 1

• Radical inguinal lymphadenectomy is indicated for cN1/cN2 disease, with adjuvant chemotherapy recommended for N2/N3 pathologic disease. 1, 5

• Neoadjuvant chemotherapy followed by radical inguinal lymphadenectomy is recommended for cN3 disease in patients who respond to chemotherapy. 5

Pathologic Risk Classification

• Low-risk tumors (≤pT1a, well-differentiated G1) have excellent prognosis and may be managed with surveillance of the inguinal regions if margins are adequate. 5

• Intermediate-risk tumors (pT1a G2) require discussion of surveillance versus surgical lymph node staging with patients willing to comply with strict follow-up protocols. 1

• High-risk tumors (≥pT1b, G3, or sarcomatoid features) mandate surgical lymph node staging regardless of clinical node status due to high rates of occult metastases. 1, 5

Critical Considerations

• Local recurrence after glansectomy does not impact cancer-specific survival when detected early—29% of patients experience local recurrence, yet 5-year cancer-specific survival remains 99%, supporting the safety of organ-sparing approaches with adequate follow-up. 3

• Penile intraepithelial neoplasia at surgical margins independently predicts local recurrence (hazard ratio 2.28), requiring either re-excision or intensive surveillance. 3

• Lymph node involvement is the primary prognostic factor—metastatic disease dramatically reduces 5-year survival to 16% in stage IV disease, making early and accurate nodal staging essential. 5, 6

• Refer patients to high-volume centers with penile cancer experience, as this rare malignancy requires specialized surgical expertise for optimal organ-sparing outcomes and lymph node management. 7, 4